Anti‐PD‐1 monoclonal antibodies (pembrolizumab, nivolumab, retifanlimab, dostarlimab, and cemiplimab) unleash deactivated immune cells by blocking the inhibitory PD‐1/PD‐L1 interaction [1], and thus reinvigorating immune response against tumor cells (Figure 1). The gene discussed is CD274; the disease is neoplasm.